Sadly, BI still talks about "loopholes"

Business Insider doesn't quite get the law about compounding — seriously, it still referred to compounding law as a "loophole" — but at least it included APC's Scott Brunner in its article, "Why copycat Ozempic is everywhere." The piece was Yet Another Article on the Current GLP-1 Landscape.

It's got some frustrating language, like, "Compounders say they have found loopholes that mean they can continue to sell copycat weight-loss drugs, despite warnings from the FDA about safety and legal threats from drugmakers Eli Lilly and Novo Nordisk."(Psst: It's not a loophole.)

Author Emily Stewart "went to a telehealth company website" (she doesn't say which) and was able to get a GLP-1 prescription without speaking to a doctor. Was it a legitimate, licensed compounder or, as seems likely, a pop-up shop that may be operating illegally? As with too many writers, it seems she doesn't get the difference.